title: Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
abstract: The definitive treatment for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who fail to respond to intravesical bacillus Calmette-Guérin (BCG) is cystectomy. However, many patients who experience recurrence after BCG are either poor operative candidates or refuse surgery due to the long-term impact on their quality of life. In the last decade, there has been an increased interest in alternative intravesical therapies, and several novel chemotherapeutics have emerged as promising agents for high-risk NMIBC patients unable or unwilling to undergo cystectomy. Additionally, extended treatment regimens with combined induction and maintenance therapy have been investigated, and may increase the durability of response to these new agents, as has been shown for conventional intravesical therapy.
authors: Department of Urology, Herbert Irving Comprehensive Cancer Center, Herbert Irving Pavilion, Columbia University Medical Center, 11th Floor 161 Fort Washington Ave., New York, NY 10032, USA. ljb2119@columbia.edu
authors: LaMont J
authors: LJ
authors: Barlow
authors: Mitchell C
authors: MC
authors: Benson
mesh_terms: D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077143:Docetaxel; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D016685:Mitomycin / Q000627:therapeutic use; D017239:Paclitaxel / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use; D013852:Thiotepa / Q000627:therapeutic use; D017211:Treatment Failure; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; C016163:valrubicin; D016685:Mitomycin; D004317:Doxorubicin; D013852:Thiotepa; D017239:Paclitaxel; D000093542:Gemcitabine
references: J Urol. 1996 Sep;156(3):962-6
references: 8709374
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: J Clin Oncol. 2006 Jul 1;24(19):3075-80
references: 16809732
references: Br J Urol. 1985 Dec;57(6):680-5
references: 2867800
references: J Clin Oncol. 2002 Aug 1;20(15):3193-8
references: 12149290
references: BJU Int. 2009 Oct;104(8):1098-102
references: 19389012
references: J Urol. 1984 Sep;132(3):457-9
references: 6471176
references: J Urol. 1976 Aug;116(2):180-3
references: 820877
references: Cancer Chemother Pharmacol. 1997;40(4):285-92
references: 9225946
references: Br J Urol. 1998 Aug;82(2):213-23
references: 9722756
references: J Urol. 1988 Dec;140(6):1390-3
references: 3143016
references: J Urol. 2001 Oct;166(4):1296-9
references: 11547061
references: BJU Int. 2007 Jul;100(1):33-6
references: 17552951
references: Eur Urol. 2007 Oct;52(4):1123-29
references: 17383080
references: J Urol. 2000 Mar;163(3):761-7
references: 10687972
references: Anticancer Drugs. 2010 Jan;21(1):101-6
references: 19858710
references: J Clin Oncol. 2006 Jun 20;24(18):2729-34
references: 16782913
references: J Urol. 2011 Aug;186(2):448-51
references: 21680003
references: J Urol. 2003 Sep;170(3):964-9
references: 12913751
references: J Clin Oncol. 1997 Dec;15(12):3441-5
references: 9396395
references: J Urol. 1982 Nov;128(5):1104-8
references: 6757465
references: J Urol. 1999 Apr;161(4):1124-7
references: 10081852
references: Rev Urol. 2008 Fall;10(4):281-9
references: 19145271
references: J Clin Oncol. 2005 Nov 1;23(31):7794-803
references: 16172456
references: Clin Cancer Res. 2005 Jun 1;11(11):4136-43
references: 15930349
references: J Urol. 2009 Mar;181(3):1040-5
references: 19150551
references: Urology. 2000 Aug 1;56(2):232-5
references: 10925084
references: Urology. 2010 Jan;75(1):134-7
references: 19913890
references: J Clin Oncol. 1997 Nov;15(11):3394-8
references: 9363871
references: Urology. 2005 Jan;65(1):65-9
references: 15667865
references: Urology. 1985 Oct;26(4 Suppl):27-9
references: 3931325
references: J Urol. 1988 Feb;139(2):283-5
references: 3339726
references: Urology. 2005 Oct;66(4):726-31
references: 16230125
references: J Urol. 1987 Jan;137(1):155-8
references: 3491909
references: J Urol. 1993 Sep;150(3):1018-23
references: 8102183
references: J Urol. 2003 May;169(5):1706-8
references: 12686813
references: World J Urol. 2002 Aug;20(3):158-66
references: 12196899
references: Clin Exp Immunol. 2003 Feb;131(2):206-16
references: 12562379
references: J Clin Oncol. 2010 Feb 1;28(4):543-8
references: 19841330
references: Urol Oncol. 2013 Nov;31(8):1635-42
references: 22575238
references: J Urol. 1987 Feb;137(2):220-4
references: 3806806
references: Urol Clin North Am. 1992 Aug;19(3):529-39
references: 1636237
references: Cancer Res. 2004 May 15;64(10):3386-90
references: 15150089
references: Genes Dev. 2009 Mar 15;23(6):675-80
references: 19261747
references: Urology. 1997 Mar;49(3):471-5
references: 9123721
references: Cochrane Database Syst Rev. 2012 Jan 18;1:CD009294
references: 22259002